In one paragraphArticle in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Yumu Zhang *State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. yumu_zhang@hms.harvard.edu.ORCID http://orcid.org/0009-0003-8564-8964 Qiuying Wang *School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, China.
Heng Liu *State Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0001-9195-1191 Hong ShanState Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID http://orcid.org/0000-0003-3572-8774 Yimin GuState Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Jiaqi YangState Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Yuan GaoState Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Kai WuState Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
H Eric XuState Key Laboratory of Drug Research, Center for Structure and Function of Drug Targets, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China. eric.xu@simm.ac.cn.ORCID http://orcid.org/0000-0002-6829-8144 Funding
Lingang Laboratory LGL-2612-05MOST | National Key Research and Development Program of China (NKPs) 2022YFC2703105MOST | National Key Research and Development Program of China (NKPs) 2022YFE0203600MOST | National Key Research and Development Program of China (NKPs) 2023YFA1800804MOST | National Natural Science Foundation of China (NSFC) 32130022MOST | National Natural Science Foundation of China (NSFC) 82121005MOST | National Natural Science Foundation of China (NSFC) 82273985MOST | National Natural Science Foundation of China (NSFC) 82473981MOST | National Natural Science Foundation of China (NSFC) 82495184National Science and Technology Major Project of China 2025ZD1802003Shanghai Municipal Science and Technology Major Project 2019SHZDZX02the CAS Strategic Priority Research Program XDB0830000the CAS Strategic Priority Research Program XDB1060402the CAS Strategic Priority Research Program XDB37030103
6 · The paper itselfAbstract
The Mas1 receptor, an orphan class A G-protein-coupled receptor (GPCR), plays pivotal roles in cardiovascular and anti-inflammatory regulation. Despite its therapeutic relevance, the structural mechanisms underlying Mas1 ligand binding and activation remain poorly understood. Here, we report cryo-EM structures of Mas1 bound to two chemically distinct agonists-neuropeptide FF (NPFF) and synthetic small-molecule AR234958-captured in complex with inhibitory G proteins. These structures reveal a conserved orthosteric binding pocket accommodating both ligands through shared hydrophobic interactions. Unlike many other class A GPCRs that rely on direct W
Indexed as
Receptors, G-Protein-CoupledBinding SitesCryoelectron MicroscopyHumansLigandsModels, MolecularProtein BindingLigandsmas-related gene-X1 receptor, humanReceptors, G-Protein-CoupledAR234958Cryo-EM StructuresGPCRMas1NPFF
Identifiers
PMID41912627
PMCPMC13187490
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390